We will apply different algorithms to measure research use statement telomere DNA abundance from sequencing data across tumors.We will study the association between tumor mutational background and telomere abundance
What are the goals of this project?
The aim of this project is to gain a better understanding of tumor heterogeneity in order to contribute to the design of future personalized medicine strategies. Specifically, I work on the integration of multiple types of genomic data derived from neuroblastoma patients to identify novel molecular groups and subsequently describe their specific genetic/epigenetic alterations and associated phenotypic effects.
What is the impact of this project?
Application of this knowledge can identify tumor vulnerabilities and opportunities for therapeutic intervention.
The Children's Brain Tumor Network contributed to this project by providing access to the Pediatric Brain Tumor Atlas.
Kristina A. Cole, MD, PhD
Kristina Cole, MD, PhD is a pediatric oncologist who has dedicated her career to translational and clinical research, combining her expertise in molecular pathology, cancer genomics, and developmental therapeutics to identify novel treatments for children with cancer. The long-term goal of Dr. Co
Children’s Hospital of Philadelphia
High-grade glioma/astrocytoma (WHO grade III/IV)
High-grade Gliomas (HGG) in children nearly always result in a dismal prognosis. Although novel therapeutic approaches are currently in development, preclinical testing has been limited, due to a lack of pediatric specific HGG preclinical models. These models are needed to help test the effective
Targeting Replicative Stress in Pediatric Brain Tumors with ALT
DNA replication in cancer cells is often accompanied by stalling and collapse of the replication fork, providing a therapeutic vulnerability if unable to be repaired. Endogenous replication stress occurs when the replication fork stalls, but the MCM helicase continues to unwind downstream causing
Kristina A. Cole